MedTrace Logo

Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing

NCT07048184 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-07-09

No results posted yet for this study

Summary

To compare the differences in clinical outcomes and health economics between standard absorbent dressings versus Negative Pressure Wound Therapy dressings following the surgical resection of sarcoma tumours.

Conditions

  • Sarcoma
  • Negative Pressure Therapy
  • Wound Complication

Interventions

DEVICE

Negative Pressure Wound Therapy (NPWT) Dressings

During wound closure, skin glue is not permitted as this interferes with the NPWT suction mechanism. The NPWT is a mesh-based dressing that will be applied following the transparent occlusive dressing as per the manufacturer's instructions. Patients assigned to NPWT will have their dressing connected to a suction device (ActiV.A.C.®, KCI) providing a constant negative pressure of 125mmHg and left in situ for between 5 and 7 days. The dressings and suction device are all CE-marked medical devices that are being used within their intended usage.

DEVICE

Standard Absorbent Dressings

The wound will be closed as per the standard surgical technique and the operating surgeon's preference. Following wound closure of sarcoma tumour resection, standard absorbent dressing will be applied as per local protocols and the pre-op plan

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • Solventum

    collaborator INDUSTRY

  • Sarcoma UK

    collaborator UNKNOWN

  • CRUK Trials unit Glasgow

    collaborator UNKNOWN

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Sanjay Gupta, MBBS, MRCS, MSc, MPhil, FRCS · Department of Trauma and Orthopaedics, Glagow Royal Infirmary, NHS Greater Glasgow and Clyde

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2027-02-28
Completion
2027-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07048184 on ClinicalTrials.gov